Bioaffinity Technologies vs Neuraxis
Bioaffinity Technologies is the larger business, with $6.2m of revenue in fiscal 2025 against $3.6m for Neuraxis (1.7 times as much). Neuraxis grew faster (32.9% against -34.2%). Neuraxis kept more of each dollar of sales as profit: a net margin of -218.5% against -242.0%. Bioaffinity Technologies carries less debt relative to equity (2.0% against 4.4%).
| Latest fiscal year | Bioaffinity TechnologiesBIAF, 2025 | NeuraxisNRXS, 2025 |
|---|---|---|
| Revenue | $6.2m | $3.6m |
| Revenue growth | -34.2% | 32.9% |
| Net income | −$14.9m | −$7.8m |
| Operating margin | -171.6% | -219.4% |
| Net margin | -242.0% | -218.5% |
| Return on equity | — | — |
| Free cash flow | −$9.4m | −$6.5m |
| Cash | $6.4m | $5.0m |
| Total debt | $146,474 | $148,293 |
| Debt to equity | 2.0% | 4.4% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 57 | 24 |
| Market value | $21.0m | $83.3m |
| Price vs our value range | — | — |
| Moat score | — | — |
| Insider trades, 12 months | 0 buys, 0 sales | 9 buys, 0 sales |